ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.2000
-0.3000 (-12.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.5000
Open2.4600
Bid0.0000 x 1000
Ask2.7300 x 1000
Day's Range2.0800 - 2.4712
52 Week Range2.0800 - 26.8500
Volume252,105
Avg. Volume534,123
Market Cap17.646M
Beta (3Y Monthly)4.76
PE Ratio (TTM)N/A
EPS (TTM)-6.9980
Earnings DateSep 9, 2019 - Sep 13, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.65
Trade prices are not sourced from all markets
  • ACCESSWIRE7 days ago

    Advaxis, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Advaxis, Inc. (NASDAQ: ADXS ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on June 11, 2019 at 11:00 AM Eastern ...

  • Business Wire8 days ago

    Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

    Conference call to be held June 11 at 11:00 a.m. ET

  • Business Wire14 days ago

    Advaxis to Host Business Update Conference Call on June 11, 2019

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the company will host a business update call on Tuesday, June 11, 2019 at 11:00 a.m. ET. During the call, Advaxis’ senior management will review the company’s clinical development programs and recent financial results, and provide a general business update. The company intends to issue a news release summarizing financial results for the fiscal second quarter ended April 30, 2019 after market close on Monday, June 10, 2019.

  • What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?
    Simply Wall St.24 days ago

    What Kind Of Investor Owns Most Of Advaxis, Inc. (NASDAQ:ADXS)?

    The big shareholder groups in Advaxis, Inc. (NASDAQ:ADXS) have power over the company. Large companies usually have...

  • Benzingalast month

    Advaxis Shares Climb After FDA Lifts Partial Clinical Hold On Cervical Cancer Drug

    Nanocap Advaxis, Inc. (NASDAQ: ADXS ) is seeing strength Wednesday following an announcement concerning its cervical cancer drug. What Happened Advaxis announced the lifting of a partial clinical hold ...

  • Business Wirelast month

    FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that the U.S. Food and Drug Administration (FDA or Agency) has lifted the partial clinical hold on AIM2CERV, the company’s Phase 3 clinical trial of axalimogene filolisbac (AXAL) for the treatment of patients with high-risk locally advanced cervical cancer. In its letter, the FDA acknowledged that the company satisfactorily addressed all hold questions. As announced on January 23, 2019, the FDA placed a partial clinical hold on this study relating to the Agency’s requests for additional information pertaining to certain AXAL chemistry, manufacturing and controls (CMC) matters. The Agency did not cite any safety issues related to the trial and all enrolled patients continued to receive treatment, per the trial protocol.

  • Business Wirelast month

    Advaxis Announces Two Poster Presentations at the Frontiers in Cancer Immunotherapy Conference

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of two posters at the Frontiers in Cancer Immunotherapy conference, being held today at the New York Academy of Sciences in New York City. Both posters were first presented at the recent American Association for Cancer Research (AACR) Annual Meeting, and each has updated findings being presented today. The first presentation regarding a poster entitled “Effects of ADXS-PSA With or Without Pembrolizumab on Survival and Antigen Spreading in Metastatic, Castration-Resistant Prostate Cancer Patients (Results from KEYNOTE-046)” is conference poster #31, and will be presented by Robert Petit, Ph.D., Advaxis Chief Scientific Officer, and Mark N. Stein, M.D., FACS, Associate Professor of Medical Oncology at Columbia University Medical Center, from 4:45 to 5:30 p.m. Eastern time.

  • Business Wirelast month

    Advaxis Announces Appointment of Dr. Robert Petit to Chair of Scientific Advisory Board and Departure as Chief Scientific Officer

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Robert Petit, Ph.D. will be leaving his position as Chief Scientific Officer at the end of the month. Dr. Petit will assist the Company in transitioning his duties over the next several weeks, and will continue to support the Company as an advisor and consultant in his capacity as the new Chair of the Advaxis Scientific Advisory Board, effective June 3, 2019.

  • Business Wirelast month

    Advaxis to Participate in Five Upcoming Industry Conferences

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces participation in f

  • Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know
    Zacks2 months ago

    Advaxis (ADXS) Stock Sinks As Market Gains: What You Should Know

    Advaxis (ADXS) closed the most recent trading day at $3.29, moving -0.3% from the previous trading session.

  • QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
    Zacks2 months ago

    QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

    QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

  • Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session
    Zacks2 months ago

    Twist Bioscience (TWST) Looks Good: Stock Adds 6.5% in Session

    Twist Bioscience (TWST) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?
    Zacks2 months ago

    Is Advaxis (ADXS) Outperforming Other Medical Stocks This Year?

    Is (ADXS) Outperforming Other Medical Stocks This Year?

  • Why Range Resources, Advaxis, and StoneCo Slumped Today
    Motley Fool2 months ago

    Why Range Resources, Advaxis, and StoneCo Slumped Today

    Equity offerings played a big role for two of these companies.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...

  • MarketWatch2 months ago

    Advaxis' stock plummets after public offering prices at deep discount

    Shares of Advaxis Inc. plummeted 25% to pace all premarket declines Wednesday, after the biotechnology company's public offering of shares priced at a deep discount. The company said its offering of 2.5 million shares to the public priced at $4.00 a share, or 32% below Tuesday's split-adjusted closing price of $5.90. A 1-for-15 reverse stock split went into effect on March 29. The company expects proceeds of about $10 million from the offering, which it intends to use to fund research and development of its product pipeline. Advaxis is focused on the development of immunotherapy products. The share offering comes after the stock has more than doubled year to date through Tuesday (up 107%), but has plunged 76% over the past 12 months. In comparison, the iShares Nasdaq Biotechnology ETF has gained 17% year to date and the S&P 500 has advanced 14%.

  • Business Wire2 months ago

    Advaxis Announces Pricing of Its Public Offering of Common Stock

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $4.00 per share. The gross proceeds to Advaxis, Inc. from this offering are expected to be approximately $10,000,000, before deducting underwriting discounts and commissions and other estimated offering expenses.

  • Business Wire3 months ago

    Advaxis, Inc. Announces Proposed Public Offering of Common Stock

    Advaxis, Inc. (ADXS) (the “Company”), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it intends to offer and sell in an underwritten public offering shares of its common stock. Electronic copies of the preliminary prospectus supplement and prospectus may be obtained, when available, from A.G.P./Alliance Global Partners, 590 Madison Avenue, 36th Floor, New York, NY 10022 or via telephone at 212-624-2060 or via email at prospectus@allianceg.com.

  • Advaxis Up on Positive Early-Stage Immunotherapy Study Data
    Zacks3 months ago

    Advaxis Up on Positive Early-Stage Immunotherapy Study Data

    Advaxis' (ADXS) immunotherapy candidate, ADXS-PSA, achieves favorable overall survival in mCRPC patients in combination with Merck's Keytruda.

  • Why Wynn Resorts, Advaxis, and Roku Jumped Today
    Motley Fool3 months ago

    Why Wynn Resorts, Advaxis, and Roku Jumped Today

    These stocks jumped on a strong start to the second quarter.

  • Why Advaxis Stock Skyrocketed 13.8% Today
    Motley Fool3 months ago

    Why Advaxis Stock Skyrocketed 13.8% Today

    The small-cap biotech reported encouraging news about its prostate cancer therapy.

  • Benzinga3 months ago

    Advaxis Shares Surge After Positive Clinical Trial Updates

    Advaxis, Inc. (NASDAQ: ADXS ) has announced a reverse stock split and clinical trial updates at the American Association of Cancer Research annual meeting in recent days. Investors have viewed the developments ...

  • ACCESSWIRE3 months ago

    Reverse Split and New Clinical Data, What's Next for Advaxis?

    NEW YORK, NY / ACCESSWIRE / April 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Biotech News: Why Advaxis Stock Is Soaring Today
    InvestorPlace3 months ago

    Biotech News: Why Advaxis Stock Is Soaring Today

    Advaxis stock is flying high Monday on news concerning a Phase1/2 study of ADXS-PSA.Source: Shutterstock ADXS-PSA is Advaxis' (NASDAQ:ADXS) Listeria monocytogenes-based immunotherapies. The drug is being evaluated for use on its own, as well as with Merck's (NYSE:MRK) anti-PD-1 therapy.The study of ADXS-PSA is broken up into two separate parts. The first is Part A, which focuses on the drug's effectiveness when used on its own. The second is Part B, which tests how it does alongside MRK's drug.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe important biotech news from Advaxis today has to do with the Part B portion of the study. New from this study shows that it is performing well when it comes to tolerability. There have been no major adverse events or additive toxicity.Another strong point from the Part B section of the study includes response from T-cell's to ADXS-PSA. There was a reaction from T-cells in 75% of subjects. It's also worth noting that antigen spreading was seen in 85% of subjects.More data from the ADXS-PSA study also finds patients taking part in the study to have a long survival rate. At the cutoff time for the data in this report, the median survival rate for patients in te study was 21.1 months. * The Elite 8 Stocks to Buy for Massive Outperformance Based on the prolonged survival data and strong safety profile to date, we believe that continued clinical development of ADXS-PSA in combination with KEYTRUDA® is warranted and represents a potentially significant opportunity for Advaxis," Kenneth Berlin, President and CEO of Advaxis, said in a statement.ADXS stock was up 16% as of noon Monday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Tech Stocks That Transformed Their Business * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos * 7 Weak Blue-Chip Stocks to Trim Immediately As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Advaxis Stock Is Soaring Today appeared first on InvestorPlace.

  • Business Wire3 months ago

    ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced updated data from the Phase 1/2 KEYNOTE-046 study in metastatic, castration-resistant prostate cancer (mCRPC). This trial is being conducted in conjunction with Merck (known as MSD outside the U.S. and Canada) and is evaluating ADXS-PSA, one of Advaxis’ Listeria monocytogenes (Lm)-based immunotherapies, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.